Chippaux Jean-Philippe auteur aut IRD text journalArticle fre text/pdf born digital access The production of antivenoms, which were long deemed ineffective, dangerous and difficult to use, has improved dramatically These antibodies (immunoglobulin G) are now fragmented, purified and controlled for their quality leading to significantly better safety and facilitating their emergency use. Envenomation can result in various syndromes depending on the snake species: Viperidae venoms are highly inflammatory, hemorrhagic and necrotising, while Elapidae venoms can cause fatal respiratory paralysis. However, some Viperidae venoms can lead to asphyxiation similar to that observed in Elapidae envenomation while, conversely, Elapidae bites may be complicated by hemorrhage or necrosis, thus complicating etiologic diagnosis. Symptomatic treatment is complex, often insufficient, and frequently associated with adverse events. In contrast, antivenoms neutralize the venom and accelerate its clearance, thus providing an etiological treatment for envenomation, particularly in remote healthcare facilities in developing countries. Current formulations consist of polyvalent antivenoms covering most of the venomous species present in a specific region. The main limitation is their high cost, and the priority should be to develop new treatment strategies, including more affordable antivenoms, especially in developing countries where they are most needed. specialized SNAKE BITES EMERGENCIES CASE MANAGEMENT ANTIVENINS RISK ASSESSMENT Morsures de serpent Urgences Prise en charge personnalisée du patient. Sérums antivenimeux Évaluation des risques MONDE BENIN 050 080 197 4-5 993-1006 2013 0001-4079 https://www.documentation.ird.fr/hor/fdi:010064601 0001-4079 [F B010064601] https://www.documentation.ird.fr/hor/fdi:010064601 https://www.documentation.ird.fr/intranet/publi/2015/00/010064601.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2015-07-07 2020-10-13 fdi:010064601 fre